60 Degrees Pharmaceuticals Inc
SXTP
查看详细走势图
4.160USD
+0.310+8.05%
收盘 02/06, 16:00（美东）报价延迟15分钟
4.27M总市值
3.70市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.05%
5天
+0.24%
1月
+111.00%
6月
+215.15%
今年开始到现在
+104.60%
1年
+50.15%
查看详细走势图
TradingKey 60 Degrees Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
60 Degrees Pharmaceuticals Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名101/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价17.60。中期看，股价处于下降通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
60 Degrees Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
60 Degrees Pharmaceuticals Inc亮点
亮点风险
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
业绩高增长
公司营业收入稳步增长，连续3年增长33.28%
业绩增长期
公司处于发展阶段，最新年度总收入681.35K美元
利润高增长
公司净利润处于行业前列，最新年度总收入681.35K美元
估值高估
公司最新PE估值3.70，处于3年历史高位
机构减仓
最新机构持股52.23K股，环比减少35.34%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值20.00
分析师目标
根据
2
位分析师
买入
评级
17.600
目标均价
+301.83%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
60 Degrees Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
60 Degrees Pharmaceuticals Inc简介
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
公司代码SXTP
公司60 Degrees Pharmaceuticals Inc
CEODow (Geoffrey S)
网址https://60degreespharma.com/
相关品种
